Highlights
• Dexmedetomidine was recently found to exert myocardial protection by regulating exosome-mediated macrophage–cardiomyocyte crosstalk, thus providing more comprehensive pharmacological evidence for the use of dexmedetomidine in relieving septic myocardial injury.
• The expression of exosomal miR-29b-3p is significantly lower in the plasma of cases with sepsis and in rats subjected to a sepsis model. Thus, plasma miR-29b-3p can be considered a promising new candidate biomarker or therapeutic target for sepsis.
• The regulation of GSK-3b Ser9 phosphorylation is a new target and mechanism by which miR-29b-3p regulates autophagy.

京公网安备11010802044758号
Comments on this article